A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
for Advanced Cancer
4 locations incl. Denver
Sponsor: Shanghai Allink Biotherapeutics Co., Ltd.
Sex: All·Age: 18 - 75
Code: NCT06656390·Phase 1, Phase 2·Recruiting